rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GRI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      GRI Bio shareholders approve equity plan changes and board elections at annual meeting
      Nov 4Investing.comGRI
      GRI Bio executives to present at IPF Summit this week
      Sep 28Investing.comGRI
      GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

      GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

      Sep 14Yahoo FinanceGRI
      Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621
      Sep 8Investing.comGRI
      GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

      New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection Signals observed from at least two independent measurement modalities, including RNA sequencing, serum extracellular matrix biomarkers, spectral flow cytometry and clinical readouts, supported each of the nine pre-specified mechanistic pillars, defining a rep

      Sep 8Yahoo FinanceGRI
      12 Health Care Stocks Moving In Friday's Intraday Session
      Sep 4BenzingaGRIIMRN
      12 Health Care Stocks Moving In Thursday's Intraday Session
      Sep 3BenzingaGRI
      GRI Bio Featured in "Why Now" On-Demand Video Webcast

      Video webcast now available here LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that it is featured in a "Why Now" video webcast. During the webcast, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, discusses the Company's differentiated approach to treating idiopathic pulmonary fibrosis (IPF) through GRI-0621

      Aug 27Yahoo FinanceGRI
      GRI Bio to present Phase 2a IPF drug data at ERS Congress
      Aug 24Investing.comGRI
      GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

      LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three...

      Aug 24BarchartGRI

      This is the newest page. Registered accounts read further back.